АНАЛИЗ НА ЕФЕКТИВНОСТТА НА РАЗХОДИТЕ ЗА КОМБИНАЦИЯ ОТ ИМУНОТЕРАПИЯ И ХИМИОТЕРАПИЯ ПРИ ТРОЙНО НЕГАТИВЕН КАРЦИНОМ НА ГЪРДАТА

The study aim is to model local data for costs and health benefits of atozolizumab (АТЕ) + nanoparticle albumin-bound paclitaxel (NABPAC) in comparison with monotherapy NAB-PAC for treatment of patients with metastatic triple-negative breast carcinoma (mTNBC) in Bulgaria. The input data in the model are the assessed therapeutic efficacy and safety in the IM passion randomized multicenter clinical trial. Modeling was performed using the TreeAge Pro Healthcare Software product. A cost-effectiveness analysis was made and incremental cost-effectiveness ratio (ICER) of АТЕ + NAB-PAC in comparison with NAB-PAC for treatment of patients with mTNBC was calculated. The results showed that the combination of immunotherapy (atezolizumab) and chemotherapy (NAB-paclitaxel) prolongs statistically significantly the disease progression-free survival and the overall survival. Modeling of data for further health benefits and costs based on the clinical endpoints identified and measured in the IM passion 130 clinical trial concluded that the combination of immunotherapy and chemotherapy demonstrates therapeutic superiority in comparison with the separate administration of chemotherapy but it is not a cost-effective therapy due to its high price. [ABSTRACT FROM AUTHOR]